# Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

> **NCT04405570** · PHASE2 · COMPLETED · sponsor: **Ridgeback Biotherapeutics, LP** · enrollment: 204 (actual)

## Conditions studied

- SARS-CoV-2 Infection, COVID-19

## Interventions

- **DRUG:** Molnupiravir 200 mg
- **DRUG:** Molnupiravir 400 mg
- **DRUG:** Molnupiravir 800 mg
- **DRUG:** Placebo (PBO)

## Key facts

- **NCT ID:** NCT04405570
- **Lead sponsor:** Ridgeback Biotherapeutics, LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-19
- **Primary completion:** 2021-02-21
- **Final completion:** 2021-02-21
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2022-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405570, "Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04405570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*